
GK Daily Special Edition: The Most Expensive Comeback in Medicine — How Alzheimer's Drugs Went From Total Failure to a Twenty-Six-Thousand-Dollar Question
In June of 2021, the Food and Drug Administration approved an Alzheimer's drug over the objection of nearly its entire advisory committee. Not one member had voted that the evidence clearly supported approval. Three of them resigned in protest, and one called it possibly the worst approval decision in recent American history. Five years later, that drug is dead, pulled from the market by its own maker. And yet, the field it nearly destroyed is now in the middle of the most consequential turnaround in modern medicine.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.